By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
Over the past year there were no insider purchases at ImmunityBio, Inc.. Three insiders sold roughly $9.5 million instead.
That's worth context: executives sell for plenty of routine reasons, from scheduled trading plans to tax bills. Buying is the rarer, more telling signal.
Quarter by quarter: 3 quarters in a row of net selling by insiders. Insiders bought in 0 of the last 7 full quarters. On the institutional side, 404 funds reported holding IBRX at the end of Q2 2026, and more funds bought than sold.
Are insiders buying or selling IBRX stock?
In the last 12 months ImmunityBio, Inc. insiders made open-market purchases worth about $0 and sales worth about $9.5 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in IBRX?
The most recent open-market insider trade in IBRX was filed on 2026-10-06.
How many institutions own IBRX?
404 investment managers reported holding IBRX in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded IBRX?
No congressional trades in IBRX were reported in the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).